Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy

Journal of Virological Methods

Volumn 214, Issue , 2015, Pages 29-32

  Sarrazin, Christoph ^a   Wedemeyer, Heiner ^b   Cloherty, Gavin ^c   Cohen, Daniel E ^d   Chevaliez, Stephane ^e   Herman, Christine ^c   Bernstein, Barry ^d   Pawlotsky, Jean Michel ^e  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Abbott Molecular Inc   (United States)

^d ABBVIE INC   (United States)

^e HENRI MONDOR HOSPITAL   (France)

Author keywords

Clinical trials; Direct acting antiviral; Hepatitis c; Vial load

Indexed keywords

ABT 072; ANTIVIRUS AGENT; PARITAPREVIR; RIBAVIRIN; RITONAVIR; UNCLASSIFIED DRUG; VIRUS RNA; ABT-450; MACROCYCLIC COMPOUND;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIMIT OF QUANTITATION; LOW DRUG DOSE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PREDICTION; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; ORAL DRUG ADMINISTRATION; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; PILOT PROJECTS; PROGNOSIS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84920973193     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.11.027     Document Type: Article

References (25)

1. Colucci G., Ferguson J., Harkleroad C., Lee S., Romo D., Soviero S., Thompson J., Velez M., Wang A., Miyahara Y., Young S., Sarrazin C. Improved Cobas TaqMan hepatitis C virus test (version 2.0) for use with the high pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J. Clin. Microbiol. 2007, 45:3595-3600.
2. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2011, 55:245-264.
3. Ferenci P., Asselah T., Foster G., et al. Faldaprevir plus pegylated Interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from Startverso1, a randomised, double-blind, placebo-controlle phase III trial. J. Hepatol. 2013, 58. (abstract 1416).
4. Fevery B., Susser S., Lenz O., Cloherty G., Perner D., Picchio G., Sarrazin C. Hepatitis C virus RNA quantification with different assays: implications for protease inhibitor-based response guided therapy. Antivir Ther. 2014, 19(6):559-567.
5. Gane E.J., Stedman C.A., Hyland R.H., Ding X., Svaroskaia E., Subramanian G.M., Symonds W.T., McHutchison J.G., Pang P.S. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor Ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014 Mar, 146(3):736-743. e1.
6. Harrington P.R., Zeng W., Naeger L.K. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012, 55:1048-1057.
7. Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol. 2008, 49:634-651.
8. Lawitz E., Poordad F., Kowdley K.V., Cohen D.E., Podsadecki T., Siggelkow S., Larsen L., Menon R., Koev G., Tripathi R., Pilot-Matias T., Bernstein B. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J. Hepatol. 2013, 59:18-23.
9. Maasoumy B., Cobb B., Bremer B., Luk K., Halfon P., Aslam S., Manns M.P., Cornberg M., Wedemeyer H. Detection of low HCV viremia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment. Pharmacol. Ther. 2014 Jan, 39(1):85-92.
10. Manns M., Marcellin P., Poordad F. Simeprevir (TMC435) with PegInterferon/Ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. J. Hepatol. 2013, 58. (abstract 1413).
11. Ogawa E., Furusyo N., Murata M., Toyoda K., Eiraku K., Shimizu M., Harada Y., Mitsumoto F., Takayama K., Okada K., Kainuma M., Hayashi J. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple-therapy: a comparison of two real-time PCR assays. Antivir. Res. 2013, 99:119-124.
12. Osinusi A., Meissner E.G., Lee Y.J., Bon D., Heytens L., Nelson A., Sneller M., Kohli A., Barrett L., Proschan M., Herrmann E., Shivakumar B., Gu W., Kwan R., Teferi G., Talwani R., Silk R., Kotb C., Wroblewski S., Fishein D., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics. JAMA 2013, 310:804-811.
13. Pawlotsky J.M. Use and interpretation of virological tests for hepatitis C. Hepatology 2002, 36:S65-S73.
14. Peiffer K.H., Sarrazin C. The importance of HCV RNA measurement for tailoring treatment duration. Dig. Liver Dis. 2013, 45(Suppl. 5):S323-S331.
15. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1195-1206.
16. Sarrazin C., Dierynck I., Cloherty G., Ghys A., Janssen K., Luo D., Witek J., Buti M., Picchio G., de Meyer S. Appropriate use of Abbott RealTime HCV RNA assay in the management of HCV patients treated with telaprevir-based regimen: a retrospective analysis of the optimize study. HepDart Meeting 2013.
17. Sidharthan S., Kohli A., Sims Z., Osinusis A., Nelson A., McHutchison J., Pang P.S., Symonds W.T., Masur H., Kottilil S. Predicting response to all-oral directly acting antiviral therapy for hepatitis C using results of Roche and Abbott HCV viral load assays. Asia Pacific Association for the Study of the Liver Meeting 2014.
18. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
19. Sherman K.E., Flamm S.L., Afdhal N.H., Nelson D.R., Sulkowski M.S., Everson G.T., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011, 365:1014-1024.
20. The Global Burden of Hepatitis C Working Group The global burden of hepatitis C. J Clin. Pharmacol. 2004, 44:20-29.
21. Vermehren J., Aghemo A., Falconer K., Susser S., Lunghi G., Zeuzem S., Colombo M., Weiland O., Sarrazin C. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J. Hepatol. 2014 May, 60(5):913-919.
22. Vermehren J., Yu M.L., Monto A., Yao J.D., Anderson C., Bertuzis R., et al. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J. Clin. Virol. 2011, 52:133-137.
23. Wise M., Bialek S., Finelli L., Bell B.P., Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008, 47:1128-1135.
24. Wyles D., Nelson D., Swain D., Gish R., Lin M., Chuang S.M., Ma J., McNally J., Stamm L., Brainard D., Symmonds W., McHutchison J., Bernstein D., Thompson A., Mangia A., Jacobson I. On-treatment HCV RNA as a predictor of virologic response in sofosbuvir-containing regimens for genotype 2/3 HCV infection: analysis of the Fission, Positron and Fusion studies. Hepatology 2013, 58(Suppl.):750A.
25. Zeuzem S., Soriano V., Asselah T., Bronowicki J.P., Lohse A.W., Müllhaupt B., Schuchmann M., Bourliere M., Buti M., Roberts S.K., Gane E.J., Stern J.O., Vinisko R., Kukolj G., Gallivan J.P., Böcher W.O., Mensa F.J. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 2013, 369:630-639.